Jakinibs are increasingly utilized to treat AGS and other interferonopathies because the JAK kinases JAK1 and TYK2 mediate signaling downstream of the IFN-I receptor complex. This evidence concerns the gene TYK2 and Aicardi-Goutieres syndrome.